U.S. markets closed
  • S&P 500

    3,841.94
    +73.47 (+1.95%)
     
  • Dow 30

    31,496.30
    +572.16 (+1.85%)
     
  • Nasdaq

    12,920.15
    +196.68 (+1.55%)
     
  • Russell 2000

    2,192.21
    +45.29 (+2.11%)
     
  • Crude Oil

    66.28
    +2.45 (+3.84%)
     
  • Gold

    1,698.20
    -2.50 (-0.15%)
     
  • Silver

    25.30
    -0.17 (-0.65%)
     
  • EUR/USD

    1.1916
    -0.0063 (-0.52%)
     
  • 10-Yr Bond

    1.5540
    +0.0040 (+0.26%)
     
  • GBP/USD

    1.3834
    -0.0060 (-0.43%)
     
  • USD/JPY

    108.3600
    +0.3840 (+0.36%)
     
  • BTC-USD

    49,350.27
    +552.06 (+1.13%)
     
  • CMC Crypto 200

    982.93
    +39.75 (+4.21%)
     
  • FTSE 100

    6,630.52
    -20.36 (-0.31%)
     
  • Nikkei 225

    28,864.32
    -65.78 (-0.23%)
     

Recap: Fluidigm Q4 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Fluidigm (NASDAQ:FLDM) fell in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share fell 333.33% year over year to ($0.13), which missed the estimate of ($0.07).

Revenue of $44,608,000 up by 37.51% year over year, which missed the estimate of $50,720,000.

Guidance

Fluidigm Sees Q1 Sales $30M-$33M vs. $47.62M Est., FY21 Sales $144M-$155M Vs. $198.25M Est.

How To Listen To The Conference Call

Date: Feb 10, 2021

Time: 05:00 PM

View more earnings on FLDM

ET Webcast URL: https://edge.media-server.com/mmc/p/oq3jcsm6

Recent Stock Performance

52-week high: $12.45

52-week low: $1.17

Price action over last quarter: Up 16.53%

Company Description

Fluidigm Corp manufactures life science tools focused on the analysis of single cells and industrial applications of genomics. These tools are based on microfluidics and mass cytometry technologies. It sells instruments and consumables, including integrated fluidic circuits, assays, and reagents. Slightly more than half of the firm's revenue comes from the sale of Consumables. Fluidigm primarily sells its products to academic institutions, clinical laboratories, and biopharmaceutical companies. The majority of revenue is generated in the United States followed by EMEA and Asia-Pacific.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.